SINCE 2022
Our group is devoted to developing novel biotherapeutics that interact with the microenvironment of diseases to precisely target and modulate their progression. Drawing on our expertise in nanotechnology, biotechnology and medical science, we are developing engineered biopolymers, living biotherapeutics and extracellular vesicles to address unmet medical needs in a range of applications.
